Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

S. Z. Usmani; R. Sexton; S. Ailawadhi; J. J. Shah; J. Valent; M. Rosenzweig; B. Lipe; J. A. Zonder; S. Fredette; B. Durie; A. Hoering; B. Bartlett; R. Z. Orlowski

doi:10.1038/bcj.2015.63

Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

S. Z. Usmani, R. Sexton, S. Ailawadhi, J. J. Shah, J. Valent, M. Rosenzweig, B. Lipe, J. A. Zonder, S. Fredette, B. Durie, A. Hoering, B. Bartlett, R. Z. Orlowski

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Letter › peer-review

29 Scopus citations

Original language	English (US)
Article number	e334
Journal	Blood cancer journal
Volume	5
DOIs	https://doi.org/10.1038/bcj.2015.63
State	Published - Aug 7 2015

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/bcj.2015.63

Cite this

Usmani, S. Z., Sexton, R., Ailawadhi, S., Shah, J. J., Valent, J., Rosenzweig, M., Lipe, B., Zonder, J. A., Fredette, S., Durie, B., Hoering, A., Bartlett, B., & Orlowski, R. Z. (2015). Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood cancer journal, 5, Article e334. https://doi.org/10.1038/bcj.2015.63

Usmani, SZ, Sexton, R, Ailawadhi, S, Shah, JJ, Valent, J, Rosenzweig, M, Lipe, B, Zonder, JA, Fredette, S, Durie, B, Hoering, A, Bartlett, B & Orlowski, RZ 2015, 'Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211', Blood cancer journal, vol. 5, e334. https://doi.org/10.1038/bcj.2015.63

@article{9bc668131ad84fd093c577ee2f27140f,

title = "Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211",

author = "Usmani, {S. Z.} and R. Sexton and S. Ailawadhi and Shah, {J. J.} and J. Valent and M. Rosenzweig and B. Lipe and Zonder, {J. A.} and S. Fredette and B. Durie and A. Hoering and B. Bartlett and Orlowski, {R. Z.}",

year = "2015",

month = aug,

day = "7",

doi = "10.1038/bcj.2015.63",

language = "English (US)",

volume = "5",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma

T2 - SWOG S1211

AU - Usmani, S. Z.

AU - Sexton, R.

AU - Ailawadhi, S.

AU - Shah, J. J.

AU - Valent, J.

AU - Rosenzweig, M.

AU - Lipe, B.

AU - Zonder, J. A.

AU - Fredette, S.

AU - Durie, B.

AU - Hoering, A.

AU - Bartlett, B.

AU - Orlowski, R. Z.

PY - 2015/8/7

Y1 - 2015/8/7

UR - http://www.scopus.com/inward/record.url?scp=84938877642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938877642&partnerID=8YFLogxK

U2 - 10.1038/bcj.2015.63

DO - 10.1038/bcj.2015.63

M3 - Letter

C2 - 26252787

AN - SCOPUS:84938877642

SN - 2044-5385

VL - 5

JO - Blood cancer journal

JF - Blood cancer journal

M1 - e334

ER -

Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this